ATXN6 - Ataxin-6

ATXN6 - Ataxin-6

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background-color: #4a90d9; color: white; text-align: center;">ATXN6</th></tr>
<tr><td colspan="2" style="text-align: center; padding: 10px;"><b>Ataxin-6</b></td></tr>
<tr><th style="width: 40%;">Symbol</th><td>ATXN6</td></tr>
<tr><th>Full Name</th><td>Ataxin-6</td></tr>
<tr><th>Chromosome</th><td>12p13.31</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/8085" target="_blank">8085</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/601042" target="_blank">601042</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169189" target="_blank">ENSG00000169189</a></td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/Q9Y2Q3" target="_blank">Q9Y2Q3</a></td></tr>
<tr><th>Protein Length</th><td>818 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>Spinocerebellar Ataxia Type 6 (SCA6), Episodic Ataxia Type 2 (EA2)</td></tr>
</table>
</div>

Overview

ATXN6 (Ataxin-6) encodes a protein of 818 amino acids that is central to the pathogenesis of Spinocerebellar Ataxia type 6 (SCA6), one of the most common autosomal dominant cerebellar ataxias worldwide. Unlike many other polyglutamine (polyQ) diseases where the disease-causing protein has unclear physiological functions, ATXN6 encodes the α1A subunit of the P/Q-type voltage-gated calcium channel (CaV2.1), a critical ion channel protein essential for normal neuronal function [@du2013].

ATXN6 - Ataxin-6

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background-color: #4a90d9; color: white; text-align: center;">ATXN6</th></tr>
<tr><td colspan="2" style="text-align: center; padding: 10px;"><b>Ataxin-6</b></td></tr>
<tr><th style="width: 40%;">Symbol</th><td>ATXN6</td></tr>
<tr><th>Full Name</th><td>Ataxin-6</td></tr>
<tr><th>Chromosome</th><td>12p13.31</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/8085" target="_blank">8085</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/601042" target="_blank">601042</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169189" target="_blank">ENSG00000169189</a></td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/Q9Y2Q3" target="_blank">Q9Y2Q3</a></td></tr>
<tr><th>Protein Length</th><td>818 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>Spinocerebellar Ataxia Type 6 (SCA6), Episodic Ataxia Type 2 (EA2)</td></tr>
</table>
</div>

Overview

ATXN6 (Ataxin-6) encodes a protein of 818 amino acids that is central to the pathogenesis of Spinocerebellar Ataxia type 6 (SCA6), one of the most common autosomal dominant cerebellar ataxias worldwide. Unlike many other polyglutamine (polyQ) diseases where the disease-causing protein has unclear physiological functions, ATXN6 encodes the α1A subunit of the P/Q-type voltage-gated calcium channel (CaV2.1), a critical ion channel protein essential for normal neuronal function [@du2013].

SCA6 is characterized by pure cerebellar ataxia, typically presenting in mid-adulthood with a chronic progressive course. The disease results from a small expansion of a CAG trinucleotide repeat within the CACNA1A gene (which encodes ataxin-6/CaV2.1), leading to a polyglutamine expansion in the channel protein. This is distinct from the classic polyglutamine diseases in that the mutation affects an ion channel rather than a transcriptional regulator or aggregate-prone protein [@gomez2017].

Interestingly, ATXN6/CAV2.1 is also allelic with two other conditions: Familial Hemiplegic Migraine type 2 (FHM2) and Episodic Ataxia Type 2 (EA2), demonstrating the remarkable phenotypic diversity that can result from different mutations in the same gene [@kord2019].

Gene Structure and Protein Architecture

The CACNA1A gene (also known as ATXN6 in the context of SCA6) spans approximately 300 kb on chromosome 12p13.31 and encodes the α1A subunit of the P/Q-type calcium channel. Key structural features include:

Protein Domains

Channel Structure

The CaV2.1 channel is a large transmembrane complex consisting of:

• α1A subunit (pore-forming, voltage sensor)
• β (auxiliary subunit)
• α2δ (auxiliary subunit)
• γ (auxiliary subunit, in some configurations)

Normal Biological Functions

The CaV2.1 (α1A) calcium channel performs essential functions in neurons:

Neurotransmitter Release

P/Q-type calcium channels are the primary voltage-gated calcium channels at presynaptic terminals, particularly in cerebellar Purkinje cells and granule cells. They initiate synaptic vesicle fusion and neurotransmitter release [@mariotti2005].

Neuronal Signaling

• Calcium influx: Mediates depolarization-triggered calcium entry
• Fast synaptic transmission: Essential for reliable synaptic signaling
• Gene expression: Calcium influx triggers downstream signaling cascades

Cerebellar Function

In the cerebellum, CaV2.1 channels are critical for:

• Purkinje cell output: Regulate the sole output of the cerebellar cortex
• Synaptic plasticity: Mediate long-term depression (LTD) at parallel fiber-Purkinje cell synapses
• Motor learning: Essential for motor coordination and adaptation

Expression Patterns

CNS Expression

CaV2.1 (α1A) is expressed predominantly in the central nervous system:

• Cerebellum: Highest expression in Purkinje cells (the primary cell type affected in SCA6)
• Cerebral cortex: Layer 2/3 pyramidal neurons
• Hippocampus: CA1-CA3 pyramidal cells
• Basal ganglia: Striatal medium spiny neurons
• Brainstem: Various motor and sensory nuclei

Peripheral Expression

Lower expression in:

• Cardiac muscle
• Smooth muscle
• Endocrine tissues

Disease Associations

Spinocerebellar Ataxia Type 6 (SCA6)

Epidemiology: SCA6 accounts for approximately 10-15% of all autosomal dominant cerebellar ataxias, making it one of the most common SCAs worldwide.

Genetics:

• Inheritance: Autosomal dominant
• Mutation: CAG repeat expansion in the CACNA1A gene
• Normal repeat: 4-16 glutamines
• Disease repeat: 19-33 glutamines (reduced penetrance above 18)
• Anticipation: Earlier onset in successive generations (modest)

• Onset: Typically 40-60 years (range 19-71 years)
• Core symptom: Progressive cerebellar ataxia
• Gait instability and truncal ataxia
• Limb dysmetria and incoordination
• Dysarthria (scanning speech)
• Nystagmus (horizontal, gaze-evoked)
• Disease course: Slow progression over decades
• Cognitive function: Generally preserved (unlike SCA17)

Episodic Ataxia Type 2 (EA2)

EA2 is allelic with SCA6 but caused by different CACNA1A mutations:

• Truncating mutations: Nonsense and frameshift mutations
• Missense mutations: Amino acid substitutions affecting channel function

• Ataxia episodes: Lasting hours to days
• Frequency: Weekly to monthly episodes
• Triggers: Stress, fatigue, caffeine, alcohol
• Baseline: Progressive ataxia between episodes
• Associated features: Migraine, vertigo, diplopia

Familial Hemiplegic Migraine Type 2 (FHM2)

Another allelic disorder caused by CACNA1A mutations:

• Core feature: Migraine with aura including hemiparesis
• Can co-occur with EA2: Some patients have both conditions
• Pathogenesis: Altered calcium channel function affects cortical excitability

Molecular Mechanisms of Neurodegeneration

Calcium Channel Dysfunction

The polyglutamine expansion in CaV2.1 produces several functional abnormalities:

Purkinje Cell Degeneration

SCA6 primarily affects cerebellar Purkinje cells:

• Selective vulnerability: Purkinje cells depend heavily on CaV2.1 function
• Synaptic impairment: Dysfunction at parallel fiber and climbing fiber synapses
• Dendritic pathology: Loss of dendritic spines and branching
• Cell death: Progressive degeneration over decades

Downstream Effects

• Transcriptional changes: Disrupted calcium-dependent gene expression
• Proteostatic stress: Impaired protein quality control
• Oxidative stress: Mitochondrial dysfunction secondary to calcium dysregulation
• Synaptic plasticity deficits: Impaired motor learning

Therapeutic Approaches

Symptomatic Treatments

• Acetazolamide: For EA2, effective in reducing episode frequency
• 4-aminopyridine: May reduce ataxia severity in some SCA6 patients
• Physical therapy: Maintain function and prevent falls
• Speech therapy: Manage dysarthria

Disease-Modifying Strategies

• Gene therapy: AAV vectors encoding wild-type CACNA1A
• RNA interference: siRNA targeting mutant allele
• Antisense oligonucleotides: Reduce mutant protein expression
• Calcium channel modulators: Enhance remaining channel function

Experimental Approaches

• Stem cell therapy: Transplantation of Purkinje cell progenitors
• Neurotrophic factors: BDNF and related molecules
• Small molecule screening: Identify neuroprotective compounds

Research Directions

Current research focuses on:

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia)
• [Polyglutamine Diseases](/mechanisms/polyglutamine-diseases)
• [Calcium Channel](/mechanisms/calcium-signaling-pathway)
• [CACNA1A Gene](/genes/cacna1a)
• [Cerebellum](/brain-regions/cerebellum)
• [Purkinje Cells](/cell-types/purkinje-cells)

External Links

• [NCBI Gene: CACNA1A](https://www.ncbi.nlm.nih.gov/gene/773)
• [Ensembl: ENSG00000057377](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000057377)
• [UniProt: Q00962](https://www.uniprot.org/uniprot/Q00962)
• [OMIM: 601042](https://www.omim.org/entry/601042)

References